 This trial is conducted in Europe. This trial aims to ensure that there is no substantial clinically relevant difference between the two Novo Nordisk needles NovoFine 6 x 0.30 mm and NovoFine 8 x 0.30 mm on reflux of insulin back to the surface of cutis. 